Adage Capital Partners Gp, L.L.C. Travere Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$56.4 Billion
Q2 2025

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,784,000 shares of TVTX stock, worth $64.1 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

2,784,000

Previous 2,184,898 27.42%

Holding current value

$64.1 Million

Previous $39.2 Million 5.24%

% of portfolio

0.07%

Previous 0.08%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$13.49 - $21.54 $8.08 Million - $12.9 Million	599,102 Added 27.42%	2,784,000 $41.2 Million
Q1 2025 May 15, 2025	BUY	$17.07 - $23.75 $30.9 Million - $42.9 Million	1,808,098 Added 479.86%	2,184,898 $39.2 Million
Q4 2024 Feb 14, 2025	SELL	$13.65 - $19.85 $316,680 - $460,520	-23,200 Reduced 5.8%	376,800 $6.56 Million
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $526,000 - $827,999	-100,000 Reduced 20.0%	400,000 $3.29 Million
Q4 2023 Feb 14, 2024	BUY	$5.44 - $9.5 $2.72 Million - $4.75 Million	500,000 New	500,000 $4.5 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $27 Million - $34.7 Million	1,513,962 Added 58.23%	4,113,962 $92.5 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $4.62 Million - $6.54 Million	250,000 Added 10.64%	2,600,000 $54.7 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $9.16 Million - $11.5 Million	400,000 Added 20.51%	2,350,000 $57.9 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $9.37 Million - $13.4 Million	447,508 Added 29.78%	1,950,000 $47.2 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $4.72 Million - $6.12 Million	200,000 Added 15.36%	1,502,492 $38.7 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $9.68 Million - $12.4 Million	-397,508 Reduced 23.38%	1,302,492 $40.4 Million
Q3 2021 Nov 15, 2021	SELL	$12.98 - $25.03 $24.6 Million - $47.4 Million	-1,893,763 Reduced 52.7%	1,700,000 $41.2 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $13.5 Million - $25.2 Million	-956,237 Reduced 21.02%	3,593,763 $52.4 Million
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $39.7 Million - $54 Million	1,700,000 Added 59.65%	4,550,000 $114 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $54.6 Million - $79.4 Million	2,850,000 New	2,850,000 $77.7 Million

Others Institutions Holding TVTX

# of Institutions

230

Shares Held

102M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.48B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Travere Therapeutics, Inc. Transaction History